US88025U1097 - Common Stock
10X GENOMICS INC-CLASS A
NASDAQ:TXG (11/11/2024, 8:06:48 PM)
Premarket: 15.91 +0.01 (+0.06%)15.9
+0.26 (+1.66%)
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,259 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
10X GENOMICS INC-CLASS A
6230 Stoneridge Mall Road
Pleasanton CALIFORNIA 94588
P: 19254017300
CEO: Serge Saxonov
Employees: 1259
Website: https://www.10xgenomics.com/
/PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Cure51...
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended...
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended...
The company is undergoing a reorganization that has proven more "disruptive" than previously expected.
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter...
Here you can normally see the latest stock twits on TXG, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: